Zaltrap Solution, Concentrate
NDC Package 0024-5840-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Zaltrap (ziv-aflibercept) solution is ziv-aflibercept is used to treat cancer of the colon and rectum. This formulation utilizes a solution, concentrate delivery system. Marketed by Sanofi-aventis U.s. Llc, this product is identified by NDC 0024-5840 and is authorized under FDA application BLA125418.

Identification & Billing

NDC Package Code
0024-5840-03
Package Description
3 VIAL in 1 CARTON / 4 mL in 1 VIAL
Product Code
0024-5840
11-Digit Billing Format
00024584003
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Zaltrap
Non-Proprietary Name
Ziv-aflibercept
Substance Name
Aflibercept
Dosage Form
Solution, Concentrate - A liquid preparation (i.e., a substance that flows readily in its natural state) that contains a drug dissolved in a suitable solvent or mixture of mutually miscible solvents; the drug has been strengthened by the evaporation of its nonactive parts.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
AFLIBERCEPT 100 mg/4mL
Pharmacologic Class
Usage Information
Ziv-aflibercept is used to treat cancer of the colon and rectum.

Regulatory & Marketing

Labeler Name
Sanofi-aventis U.s. Llc
Product Type
Human Prescription Drug
FDA Application #
BLA125418
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
08-03-2012
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0024-5840). Click a package code to view its specific billing and regulatory data.

0024-5840-01
1 VIAL in 1 CARTON / 4 mL in 1 VIAL

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0024-5840-03 identifies a specific commercial package of 3 vial in 1 carton / 4 ml in 1 vial of Zaltrap, a human prescription drug labeled by Sanofi-aventis U.s. Llc. This solution, concentrate is formulated for intravenous use and contains aflibercept as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi-aventis U.s. Llc on August 03, 2012. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Ziv-aflibercept is used to treat cancer of the colon and rectum.

How is this Sanofi-aventis U.s. Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00024584003. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0024-5840-03
11-Digit CMS (5-4-2)
00024-5840-03

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.